Removal of Vaccinia Virus Genes That Block Interferon Type I and II Pathways Improves Adaptive and Memory Responses of the HIV/AIDS Vaccine Candidate NYVAC-C in Mice

MVA and NYVAC as Vaccines against Emergent Infectious Diseases and Cancer

(2011) Carmen E. Gomez et al.   CURRENT GENE THERAPY

Glycosaminoglycans mediate retention of the poxvirus type I interferon binding protein at the cell surface to locally block interferon antiviral responses

(2011) Imma Montanuy et al.   FASEB JOURNAL

Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine

(2011) Scott G. Hansen et al.   NATURE

Improved Innate and Adaptive Immunostimulation by Genetically Modified HIV-1 Protein Expressing NYVAC Vectors

(2011) Esther D. Quakkelaar et al.   PLoS One

A Candidate HIV/AIDS Vaccine (MVA-B) Lacking Vaccinia Virus Gene C6L Enhances Memory HIV-1-Specific T-Cell Responses

(2011) Juan García-Arriaza et al.   PLoS One

Improved NYVAC-Based Vaccine Vectors

(2011) Karen V. Kibler et al.   PLoS One

Immunization with HIV Gag targeted to dendritic cells followed by recombinant New York vaccinia virus induces robust T-cell immunity in nonhuman primates

(2011) B. J. Flynn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Different patterns of expansion, contraction and memory differentiation of HIV-1 Gag-specific CD8 T cells elicited by adenovirus type 5 and modified vaccinia Ankara vaccines

(2011) Vinod Kumar Bhaskara Pillai et al.   VACCINE

Vaccinia Virus Protein C6 Is a Virulence Factor that Binds TBK-1 Adaptor Proteins and Inhibits Activation of IRF3 and IRF7

(2011) Leonie Unterholzner et al.   PLoS Pathogens

IFN-  Receptor Signaling Regulates Memory CD8+ T Cell Differentiation

(2010) O. Sercan et al.   JOURNAL OF IMMUNOLOGY

Insertion of Vaccinia Virus C7L Host Range Gene into NYVAC-B Genome Potentiates Immune Responses against HIV-1 Antigens

(2010) José Luis Nájera et al.   PLoS One

Immunogenic Profiling in Mice of a HIV/AIDS Vaccine Candidate (MVA-B) Expressing Four HIV-1 Antigens and Potentiation by Specific Gene Deletions

(2010) Juan García-Arriaza et al.   PLoS One

Poxvirus vector-based HIV vaccines

(2010) Giuseppe Pantaleo et al.   Current Opinion in HIV and AIDS

The Interferon System and Vaccinia Virus Evasion Mechanisms

(2009) Beatriz Perdiguero et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

Immunization with Live Attenuated Influenza Viruses That Express Altered NS1 Proteins Results in Potent and Protective Memory CD8+ T-Cell Responses

(2009) S. N. Mueller et al.   JOURNAL OF VIROLOGY

Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand

(2009) Supachai Rerks-Ngarm et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preclinical Evaluation of the Immunogenicity of C-Type HIV-1-Based DNA and NYVAC Vaccines in the Balb/C Mouse Model

(2009) Jens Wild et al.   VIRAL IMMUNOLOGY

An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses

(2008) Alexandre Harari et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Vaccinia Virus-Mediated Inhibition of Type I Interferon Responses Is a Multifactorial Process Involving the Soluble Type I Interferon Receptor B18 and Intracellular Components

(2008) Z. Waibler et al.   JOURNAL OF VIROLOGY

Differential CD4+ versus CD8+ T-Cell Responses Elicited by Different Poxvirus-Based Human Immunodeficiency Virus Type 1 Vaccine Candidates Provide Comparable Efficacies in Primates

(2008) P. Mooij et al.   JOURNAL OF VIROLOGY

Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA)

(2008) Matthew G. Cottingham et al.   PLoS One

EV01: A phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium

(2008) Pierre-Alexandre Bart et al.   VACCINE

EV02: A Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone

(2008) Sheena McCormack et al.   VACCINE